keyword
MENU ▼
Read by QxMD icon Read
search

DMARDs

keyword
https://www.readbyqxmd.com/read/28448195/design-characteristics-of-the-corrona-japan-rheumatoid-arthritis-registry
#1
Hisashi Yamanaka, Mitsumasa Kishimoto, Dimitrios A Pappas, Jeffrey D Greenberg, Joel M Kremer, Yoshiya Tanaka
OBJECTIVES: The primary objective is to prospectively study the comparative safety and effectiveness of older and newer classes of nonbiologic DMARDs (Disease-modifying antirheumatic drugs), biologic DMARDs and targeted synthetic therapies approved for rheumatoid arthritis (RA) in a real-world patient population in Japan. METHODS: Prospective, multicenter, noninterventional, observational study across geographic distribution of both private and public institutions for patients with RA who are newly prescribed one of the following medications: (1) methotrexate; (2) anti-TNF biologic DMARDs; (3) non-TNF biologic DMARDs; and (4) approved JAK inhibitors at the time of enrollment into the registry...
April 27, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28446212/doctors-preferences-in-de-escalating-dmards-in-rheumatoid-arthritis-a-discrete-choice-experiment
#2
T Martijn Kuijper, Riëtte Folmer, Elly A Stolk, Johanna M W Hazes, Jolanda J Luime
BACKGROUND: Current guidelines suggest reduction of DMARDs can be considered in RA patients in remission. Objectives were (1) to estimate the relative importance of patient characteristics rheumatologists consider in their decision to de-escalate (2) to assess whether heterogeneity exists among rheumatologists with respect to de-escalation and (3) to identify the preferred de-escalation strategy. METHODS: A discrete choice experiment (DCE) was conducted. All rheumatologists and trainees in The Netherlands were invited to participate...
April 26, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28445107/hypodermal-adipose-tissue-sonoelastography-for-monitoring-treatment-response-in-patients-with-plaque-psoriasis
#3
Annunziata Dattola, Simone Altobelli, Salvatore Marsico, Domenico Plastina, Steven P Nistico, Armando Cavallo, Roberto Floris, Luca Bianchi, Manlio Guazzaroni
BACKGROUND: Psoriasis (PsO) is a multifactorial chronic and relapsing skin disease that affects about 125 million people in the world. Several studies have demonstrated the link between adipose tissue, inflammation, and PsO. The purpose of our study is to evaluate hypodermal adipose tissue inflammation underneath PsO plaques quantifying tissue elasticity with sonoelastography before and after treatment. The study was conducted at the Department of Dermatology of the University of "Rome Tor Vergata" and Department of Radiology of the University of "Rome Tor Vergata...
April 24, 2017: Photomedicine and Laser Surgery
https://www.readbyqxmd.com/read/28444172/risk-of-venous-thromboembolism-in-patients-with-psoriatic-arthritis-psoriasis-and-rheumatoid-arthritis-a-general-population-based-cohort-study
#4
Alexis Ogdie, Neilia Kay McGill, Daniel B Shin, Junko Takeshita, Thorvardur Jon Love, Megan H Noe, Zelma C Chiesa Fuxench, Hyon K Choi, Nehal N Mehta, Joel M Gelfand
Aims: To determine the risk of venous thromboembolism (VTE) defined as the combined endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE) among patients with psoriatic arthritis (PsA), psoriasis and rheumatoid arthritis (RA) compared with population controls. Methods and results: A cohort study was conducted in a primary care medical record database in the UK with data from 1994-2014 among patients with PsA, RA, or psoriasis. Cox proportional hazards models were used to calculate the relative hazards for DVT, PE, and VTE...
April 20, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28441950/development-of-a-web-based-patient-decision-aid-for-initiating-disease-modifying-anti-rheumatic-drugs-using-user-centred-design-methods
#5
Ingrid Nota, Constance H C Drossaert, Heleen C Melissant, Erik Taal, Harald E Vonkeman, Cees J Haagsma, Mart A F J van de Laar
BACKGROUND: A main element of patient-centred care, Patient Decision Aids (PtDAs) facilitate shared decision-making (SDM). A recent update of the International Patient Decision Aids Standards (IPDAS) emphasised patient involvement during PtDA development, but omitted a methodology for doing so. This article reports on the value of user-centred design (UCD) methods for the development of a PtDA that aims to support inflammatory arthritis patients in their choice between disease modifying anti-rheumatic drugs (DMARDs)...
April 26, 2017: BMC Medical Informatics and Decision Making
https://www.readbyqxmd.com/read/28431162/risk-of-serious-bacterial-infection-associated-with-tumour-necrosis-factor-alpha-inhibitors-in-children-with-juvenile-idiopathic-arthritis
#6
Wan-Ju Lee, Todd A Lee, Katie J Suda, Gregory S Calip, Leslie Briars, Glen T Schumock
Objectives.: TNF-α inhibitors (TNFIs) have a black box warning for increased risk of serious infection that was based on evidence from studies of adults. Evidence of the association is lacking for children. We aimed to examine the risk of infection posed by TNFIs compared with DMARDs in children with JIA. Methods.: We conducted a cohort study using the 2009-13 Truven MarketScan Commercial Claims and Encounters database. Children <16 years old with JIA who initiated monotherapy with TNFIs or DMARDs were identified and followed for occurrence of serious bacterial infection requiring hospitalization...
April 18, 2017: Rheumatology
https://www.readbyqxmd.com/read/28429118/-how-frequent-are-poor-prognostic-markers-in-rheumatoid-arthritis-an-estimate-based-on-three-epidemiologic-cohorts
#7
K Albrecht, A Richter, Y Meissner, D Huscher, L Baganz, K Thiele, M Schneider, A Strangfeld, A Zink
BACKGROUND: Unfavorable prognostic factors-high disease activity, early erosions, and autoantibodies-should be considered when making treatment decisions in rheumatoid arthritis (RA). There are little data on the frequency of individual poor prognostic factors among RA patients in daily care. METHODS: Disease activity (Disease Activity Score, DAS28), erosions, antibodies against citrullinated peptides or rheumatoid factor (ACPA/RF+), previous treatment failure, inflammation markers, and functional disability (FFbH < 70) were defined as prognostic factors...
April 20, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28425173/the-20-year-outcome-and-association-between-early-treatment-and-mortality-and-disability-in-an-inception-cohort-of-patients-with-rheumatoid-arthritis-results-from-the-norfolk-arthritis-register
#8
James M Gwinnutt, Deborah Pm Symmons, Alexander J MacGregor, Jacqueline R Chipping, Tarnya Marshall, Mark Lunt, Suzanne Mm Verstappen
Objective - To describe the outcome of patients with rheumatoid arthritis (RA) over 20 years from symptom onset; to assess the association between early treatment (DMARDs/steroids) and mortality and disability over follow-up. Methods - Patients from the Norfolk Arthritis Register recruited from 1990-94 who met the 2010 ACR/EULAR RA criteria at baseline were included in this analysis. Demographic/clinical variables were collected at baseline and years 1-3, 5, 7, 10, 15 and 20. Disease activity (swollen/tender joint counts (SJC/TJC)), disability (HAQ) and mortality over 20 years are described...
April 20, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28422773/infections-in-rheumatoid-arthritis
#9
Fabiola Atzeni, Ignazio Francesco Masala, Manuela di Franco, Piercarlo Sarzi-Puttini
PURPOSE OF REVIEW: The purpose of this review is to provide an update concerning recent advances in the evidence- based study of serious infections in patients with rheumatoid arthritis (RA) treated with biological drugs or conventional disease-modifying antirheumatic drugs (DMARDs), concentrating on studies published in the last 18 months. RECENT FINDINGS: New studies have further strengthened existing evidence relating the use of biological drugs to serious infections...
April 18, 2017: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/28421991/patterns-in-use-and-costs-of-conventional-and-biologic-disease-modifying-anti-rheumatic-drugs-in-australia
#10
Ellen Donges, Christine Staatz, Helen Benham, Paul Kubler, Samantha A Hollingworth
OBJECTIVES: The aim of this study was to characterise the use and costs of subsidising conventional disease-modifying anti-rheumatic drugs (DMARDs) and biologic DMARDs in Australia from 2004-2014 through pharmaceutical benefits schemes. METHODS: Dispensing and expenditure data on conventional and biologic DMARDs were extracted from Medicare Australia and temporal trends were analysed. Medicine use was standardised in terms of the defined daily dose (DDD) per 1,000 population per day (DDD/1,000 population/day)...
April 18, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28420837/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-functional-remission-with-six-months-of-biological-dmards-treatment
#11
Yusuke Miwa, Ryo Takahashi, Yuzo Ikari, Airi Maeoka, Shinichiro Nishimi, Nao Oguro, Tomoki Hayashi, Mika Hatano, Sakiko Isojima, Ryo Yanai, Tsuyoshi Kasama, Yoichi Toyoshima, Katsunori Inagaki, Kenji Sanada
Objective Although previous studies have reported the prognostic factors for functional remission, no reports have cited the predictive factors. Our aim was to study the predictive factors for functional remission, which is a treatment goal in rheumatoid arthritis (RA), after receiving biological disease-modifying antirheumatic drugs (bDMARDs) treatment for six months. Methods The study consisted of 333 RA patients treated with bDMARDs for six months. The following patient characteristics were investigated: age, gender, disease duration, type of bDMARDs, baseline steroid and methotrexate dosage, and levels of serum rheumatoid factor, matrix metalloprotease, anti-cyclic citrullinated peptides antibody, tumor necrosis factor-α, and interleukin-6...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28416614/modeling-combined-immunosuppressive-and-anti-inflammatory-effects-of-dexamethasone-and-naproxen-in-rats-predicts-the-steroid-sparing-potential-of-naproxen
#12
Xiaonan Li, Debra C DuBois, Dawei Song, Richard R Almon, William J Jusko, Xijing Chen
Dexamethasone (DEX), a widely prescribed corticosteroid (CS), has long been the cornerstone for the treatment of inflammation and immunological dysfunctions in Rheumatoid Arthritis (RA). The CS are frequently used in combination with other anti-rheumatic agents such as nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying anti-rheumatic drugs (DMARDs) to mitigate disease symptoms and minimize unwanted effects. The steroid dose-sparing potential of the NSAID naproxen (NPX) was explored with in vitro and in vivo studies...
April 17, 2017: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/28415924/an-assessment-of-the-current-treatment-landscape-for-rheumatology-patients-in-qatar-recognising-unmet-needs-and-moving-towards-solutions
#13
Samar Al Emadi, Mohammed Hammoudeh, Mohamed Mounir, Ruediger B Mueller, Alvin F Wells, Housam Aldeen Sarakbi
Objective This study assessed the mode of application (oral, intravenous or subcutaneous (SC)) currently employed in the treatment of rheumatoid arthritis (RA) in patients from Qatar in comparison with patients' individual preferences for the mode of application of their treatment. Methods This study included 294 RA patients visiting three clinics at the main referral hospital in Qatar who were interviewed using a standard questionnaire to determine their preference of mode of application for their disease-modifying antirheumatic drug (DMARD) treatment in relation to their currently employed mode of application...
April 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28412711/biologic-disease-modifying-antirheumatic-drug-bdmard-induced-neutropenia-a-registry-from-a-retrospective-cohort-of-patients-with-rheumatic-diseases-treated-with-3-classes-of-intravenous-bdmard
#14
Francisco Espinoza, Pierre Le Blay, Bernard Combe
OBJECTIVE: To examine the rate, risks factors, and consequences of neutropenia induced by intravenous (IV) biologic disease-modifying antirheumatic drugs (bDMARD). METHODS: We conducted a retrospective cohort study in 499 patients with rheumatic diseases treated by IV abatacept (ABA), infliximab (IFX), or tocilizumab (TCZ). RESULTS: Rheumatoid arthritis (RA) was the most frequent diagnosis (72%). Fifty-two patients (10.4%) experienced at least 1 episode of neutropenia...
April 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28412710/triple-oral-therapy-versus-antitumor-necrosis-factor-plus-methotrexate-mtx-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-mtx-a-systematic-literature-review
#15
Julia Mary, Michel De Bandt, Cédric Lukas, Jacques Morel, Bernard Combe
OBJECTIVE: For patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX), the relative effectiveness of the combination of conventional disease-modifying antirheumatic drugs (DMARD) compared with the combination of tumor necrosis factor (TNF) inhibitors and MTX, as second-line therapy, is uncertain. The aim of this study was to compare the efficacy and tolerance of triple oral DMARD therapy versus anti-TNF agents associated with MTX in patients with RA after MTX failure...
April 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28412701/association-between-medications-and-herpes-zoster-in-japanese-patients-with-rheumatoid-arthritis-a-5-year-prospective-cohort-study
#16
Sayoko Harada, Ryoko Sakai, Fumio Hirano, Nobuyuki Miyasaka, Masayoshi Harigai
OBJECTIVE: To investigate the association between medications and herpes zoster (HZ) in patients with rheumatoid arthritis (RA) given biological disease-modifying antirheumatic drugs (bDMARD) or conventional synthetic DMARD in the clinical setting during 5 years using the Registry of Japanese Rheumatoid Arthritis Patients on Biologics for Longterm Safety (REAL) database. METHODS: We calculated the crude incidence rate (IR) of HZ treated with systemic antiviral medications in 1987 patients from the REAL database...
April 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28408801/effects-of-%C3%AE-d-mannuronic-acid-as-a-novel-non-steroidal-anti-inflammatory-medication-within-immunosuppressive-properties-on-il17-ror%C3%AE-t-il4-and-gata3-gene-expressions-in-rheumatoid-arthritis-patients
#17
Anis Barati, Ahmad Reza Jamshidi, Hossein Ahmadi, Zahra Aghazadeh, Abbas Mirshafiey
Rheumatoid arthritis (RA) is the most common form of chronic inflammatory arthritis characterized by pain, swelling and destruction of joints, with a resultant disability. Disease-modifying anti-rheumatic drugs (DMARDs) and biological drugs can interfere with the disease process. In this study, the effect of β-d-mannuronic acid (M2000) as a novel non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive and anti-inflammatory effects together with antioxidant effects was evaluated on IL17, RORγt, IL4 and GATA3 gene expression in 12 RA patients...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28408798/an-open-randomized-active-controlled-clinical-trial-with-low-dose-ska-cytokines-versus-dmards-evaluating-low-disease-activity-maintenance-in-patients-with-rheumatoid-arthritis
#18
L S Martin-Martin, F Giovannangeli, E Bizzi, U Massafra, E Ballanti, M Cassol, A Migliore
BACKGROUND: Biologic agents are currently the strongest immunosuppressive drugs able to induce remission in rheumatoid arthritis (RA). One of the objectives of the medical scientific community now is how to maintain remission or low disease activity (LDA). The aim of this trial is to evaluate the contribution of low-dose sequential kinetic activation (SKA) IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL) in patients affected by RA in maintaining LDA or remission obtained after biological therapy...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28407127/no-clear-association-between-ultrasound-remission-and-health-status-in-rheumatoid-arthritis-patients-in-clinical-remission
#19
Myrthe van der Ven, T Martijn Kuijper, Andreas H Gerards, Ilja Tchetverikov, Angelique E Weel, Jendé van Zeben, Johanna M Hazes, Jolanda J Luime
Objectives.: Although RA patients achieve clinical remission, risk of flare still exists. Given the association between US synovitis and increased risk of flare, it is of clinical interest whether these patients report a different health status. Therefore, our aim was to evaluate the frequency of US remission in RA patients in clinical remission and to compare the health status of RA patients in clinical remission with those who were also in US remission. Methods: ...
April 11, 2017: Rheumatology
https://www.readbyqxmd.com/read/28405473/patient-reported-outcomes-from-a-phase-iii-study-of-baricitinib-in-patients-with-conventional-synthetic-dmard-refractory-rheumatoid-arthritis
#20
Paul Emery, Ricardo Blanco, Jose Maldonado Cocco, Ying-Chou Chen, Carol L Gaich, Amy M DeLozier, Stephanie de Bono, Jiajun Liu, Terence Rooney, Cecile Hsiao-Chun Chang, Maxime Dougados
OBJECTIVES: To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. METHODS: In this phase III study, patients were randomised 1:1:1 to placebo (N=228), baricitinib 2 mg once daily (QD, N=229) or baricitinib 4 mg QD (N=227). PROs included the Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, measures from patient electronic daily diaries (duration and severity of morning joint stiffness (MJS), Worst Tiredness, Worst Joint Pain), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), SF-36, EuroQol 5-D index scores and visual analogue scales (VAS) and the Work Productivity and Activity Impairment Questionnaire-RA...
2017: RMD Open
keyword
keyword
86203
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"